AI is pushing breast cancer care from image reading toward full-pathway decision support
A new Cureus review argues that AI is becoming relevant across the breast cancer care continuum, from detection and pathology to prognostication and treatment planning. The literature now points to a broader clinical role than single-task image classification.
Breast cancer is one of the clearest examples of how AI in oncology is expanding from a narrow tool into a broader clinical platform. A comprehensive review is meaningful because it reflects a maturing evidence base: the conversation is no longer just about whether AI can find lesions, but whether it can influence diagnosis, staging, and treatment selection.
That shift matters because breast cancer care depends on multiple information streams. Imaging, pathology, genomics, and longitudinal follow-up all affect decisions, so AI systems that can integrate data across modalities may offer more value than models trained on one task alone.
Still, comprehensive reviews tend to expose as much uncertainty as promise. The field has produced many promising prototypes, but fewer systems have cleared the harder threshold of prospective validation, external generalizability, and clinical accountability. Those are the barriers that determine whether AI becomes a decision aid or just another research artifact.
The likely near-term outcome is not automation but augmentation. In breast oncology, AI appears best positioned to improve consistency, prioritize urgent cases, and help clinicians synthesize increasingly complex patient data. The challenge is proving that these gains translate into better outcomes rather than just faster workflows.